Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages

Journal of Interferon and Cytokine Research

Volumn 35, Issue 3, 2015, Pages 213-221

  Wang, Yizhong ^a   Li, Jieliang ^b   Wang, Xu ^b   Zhou, Yu ^b   Zhang, Ting ^a   Ho, Wenzhe ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; JANUS KINASE; LAMBDA INTERFERON 1; LAMBDA INTERFERON 2; LAMBDA INTERFERON 3; PATTERN RECOGNITION RECEPTOR; STAT PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IL28A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INHIBITION; VIRUS REPLICATION; CELL CULTURE; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANTIVIRAL AGENTS; CELLS, CULTURED; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKINS; JANUS KINASES; MACROPHAGES; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VIRUS REPLICATION;

EID: 84929177169     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0064     Document Type: Article

References (46)

1. Almeida GM, de Oliveira DB, Magalhaes CL, Bonjardim CA, Ferreira PC, Kroon EG. 2008. Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res 80(3):302-308.
2. Ank N, Paludan SR. 2009. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 35(1):82-87.
3. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Pa-ludan SR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80(9):4501-4509.
4. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Goke B, Dambacher J. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289(5): G960-G968.
5. Crouch DH, Fisher F, La Rocca SA, Goding CR, Gillespie DA. 2005. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain. Nucleic Acids Res 33(16): 5235-5242.
6. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. 2009. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 10(2):125-131.
7. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. 2013. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 93(3):377-385.
8. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S. 2010. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 5(12): e15200.
9. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. 2004. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76(2):314-321.
10. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279(31):32269-32274.
11. Gad HH, Hamming OJ, Hartmann R. 2010. The structure of human interferon lambda and what it has taught us. J Interferon Cytokine Res 30(8):565-571.
12. Hassan NF, Campbell DE, Douglas SD. 1986. Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods 95(2):273-276.
13. Ho WZ, Lioy J, Song L, Cutilli JR, Polin RA, Douglas SD. 1992. Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. J Virol 66(1):573-579.
14. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 32(3):118-128.
15. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ. 2009. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 83(8):3834-3842.
16. Jensen S, Thomsen AR. 2012. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol 86(6):2900-2910.
17. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
18. Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, Kolios G, Ward SG. 2005. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 175(8):5403-5411.
19. Lee CM, Reddy EP. 1999. The v-myc oncogene. Oncogene 18(19):2997-3003.
20. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE, Levine B, Virgin HWt. 2005. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79(22):13974-13983.
21. Li M, Liu X, Zhou Y, Su SB. 2009. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86(1):23-32.
22. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, Ho WZ. 2003. Morphine enhances hepatitis C virus (HCV) re-plicon expression. Am J Pathol 163(3):1167-1175.
23. Liu MQ, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ. 2012. IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One 7(4): e35902.
24. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastro-enterology 131(6):1887-1898.
25. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177): 425-430.
26. Okugawa S, Mekata T, Inada M, Kihara K, Shiki A, Kannabiran K, Kono T, Sakai M, Yoshida T, Itami T, Sudhakaran R. 2013. The SOCS and STAT from JAK/STAT signaling pathway of kuruma shrimp Marsupenaeus japonicus: molecular cloning, characterization and expression analysis. Mol Cell Probes 27(1):6-14.
27. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282(10):7576-7581.
28. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Ko-haar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, As-temborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164-171.
29. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281-1283.
30. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. 2011. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 85(24):12881-12889.
31. Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79(6):3851-3854.
32. Rubin BP, Heinrich MC, Corless CL. 2007. Gastrointestinal stromal tumour. Lancet 369(9574):1731-1741.
33. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1(6):519-525.
34. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Rora-back J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68.
35. Soroceanu L, Akhavan A, Cobbs CS. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455(7211):391-395.
36. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655.
37. Tanner DC, Cherry JD, Mayer-Proschel M. 2011. Oligoden-drocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-gamma. J Neurosci 31(16):6235-6246.
38. Thompson AJ, Locarnini SA. 2007. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol 85(6):435-445.
39. Uze G, Monneron D. 2007. IL-28 and IL-29: newcomers to the interferon family. Biochimie 89(6-7):729-734.
40. Wang Y, Ye L, Wang X, Li J, Song L, Ho W. 2013. Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. Innate Immun 19(2):193-202.
41. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, Martin MA. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62(1):139-147.
42. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cyto-kines. Genes Immun 10(8):702-714.
43. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Marodi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL. 2005. Human TLR-7-,-8-, and-9-mediated induction of IFN-alpha/beta and-lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23(5):465-478.
44. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. 2004. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279(51):53379-53386.
45. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. 2011. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55(2):289-298.
46. Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, Lai JP, Wang YJ, Wan Q, Ho WZ. 2005. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 42(4):819-827.